MedTrace Logo

Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus

NCT01298999 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-11-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether treatment with an experimental drug called YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.

Conditions

  • Barrett's Esophagus

Interventions

DRUG

YF476

25 mg: one capsule to be taken by mouth once daily for 12 weeks.

DRUG

Placebo

Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • Julian A Abrams, MD, MS · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01298999 on ClinicalTrials.gov